ARROWHEAD'S 2nd Annual Cancer Immunotherapy Conference will provide a comprehensive review of cutting edge research and development in two areas:

• Cancer Stem Cells as a new category of Targets for Immune Intervention for solid and hematological malignancies

• Hematopoietic Stem Cell and T Cell Engineering for cancer immunotherapy

The conference is bringing together leading scientists and C-Level executives from across the globe to present research, case studies and viewpoints on topics related to stem cells and cancer immunotherapy.

Adrian Bot, MD, Ph.D., Chief Scientific Officer, Kite Pharma Inc.

Maurizio Chiriva-Internati, DBSc, Ph.D., Director of Basic/Translational Research Program, Division of Hematology & Oncology, Southwest Cancer Research & Treatment Center at University Medical Center,Texas Tech University of Health Sciences Center School of Medicine

Andrew Cornforth, Ph.D., Cancer Stem Cell Program Manager, California Stem Cell, Inc.

Soldano Ferrone, MD, Ph.D., Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School

Kenneth Geles, Ph.D., Senior Principal Scientist, Oncology Research Unit, Pfizer Inc.

Richard C. Koya, MD, Ph.D., Assistant Professor, Department of Surgery, Surgical Oncology, Member, JCCC Tumor Immunology Program, University of California, Los Angeles

Douglas G. McNeel, MD Ph.D., Associate Professor of Medicine, University of Wisconsin

Masoud H. Manjili, DVM, Ph.D., Associate Professor, Department of Microbiology & Immunology,Virginia Commonwealth University School of Medicine

William Matsui, MD, Associate Professor of Oncology, Division of Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine

Richard A. Morgan, Ph.D., Staff Scientist, Surgery Branch, Tumor Immunology Section, National Cancer Institute

Nicholas P. Restifo, MD, Principal Investigator, Center for Cancer Research, National Cancer Institute

David M. Spencer, Ph.D., Chief Scientific Officer, Bellicum Pharmaceuticals, Inc.

Robert Tressler, Ph.D., Vice President of Research & Development, Cellerant Therapeutics, Inc.

Albert J. Wong, MD, Professor, Director, Brain Tumor Research Laboratories, Deptartment of Neurosurgery/Cancer Biology Program, Stanford University Medical Center

Lili Yang, Ph.D., Lead Scientist & Project Manager, Engineering Immunity Program, Laboratory of David Baltimore, Division of Biology, California Institute of Technology